1Department of Gastroenterology and Hepatology, University Hospital Lausanne/CHUV, Switzerland 2Department of Gastroenterology and Hepatology, University Hospital Basel, Switzerland 3Institute of Social and Preventive Medicine, University of Bern, Switzerland 4Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA 5Division of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA 6GI Outcomes Unit, Mayo Clinic, Rochester, Minnesota, USA 7Department of Gastroenterology and Hepatology, McMaster University Hospital, Hamilton, ON, Canada 8Department of Gastroenterology and Hepatology, University Hospital Jena, Germany 9Bioanalytica Medical Laboratories, Lucerne, Switzerland 10Institute of Social and Preventive Medicine, University of Lausanne, Switzerland 11Department of Gastroenterology and Hepatology, University Hospital Zurich, Switzerland.
The correlation between noninvasive markers with endoscopic activity according to the modified Baron Index in patients with ulcerative colitis (UC) is unknown. We aimed to evaluate the correlation between endoscopic activity and fecal calprotectin (FC), C-reactive protein (CRP), hemoglobin, platelets, blood leukocytes, and the Lichtiger Index (clinical score).
UC patients undergoing complete colonoscopy were prospectively enrolled and scored clinically and endoscopically. Samples from feces and blood were analyzed in UC patients and controls.
We enrolled 228 UC patients and 52 healthy controls. Endoscopic disease activity correlated best with FC (Spearman's rank correlation coefficient r = 0.821), followed by the Lichtiger Index (r = 0.682), CRP (r = 0.556), platelets (r = 0.488), blood leukocytes (r = 0.401), and hemoglobin (r = -0.388). FC was the only marker that could discriminate between different grades of endoscopic activity (grade 0, 16 [10-30] μg/g; grade 1, 35 [25-48] μg/g; grade 2, 102 [44-159] μg/g; grade 3, 235 [176-319] μg/g; grade 4, 611 [406-868] μg/g; P < 0.001 for discriminating the different grades). FC with a cutoff of 57 μg/g had a sensitivity of 91% and a specificity of 90% to detect endoscopically active disease (modified Baron Index ≥ 2).
FC correlated better with endoscopic disease activity than clinical activity, CRP, platelets, hemoglobin, and blood leukocytes. The strong correlation with endoscopic disease activity suggests that FC represents a useful biomarker for noninvasive monitoring of disease activity in UC patients.
"However, no correlation was found when comparing the serum calprotectin and C-reactive protein levels in our studies (Fig. 3). These findings confirm what other groups have found with respect to CRP and inflammation in patients with ulcerative colitis . This may have been due to the fact that the C-reactive protein levels peak at the beginning of the disease process and then decrease rapidly. "
[Show abstract][Hide abstract] ABSTRACT: Background and aim:
Serum calprotectin is elevated in patients with inflammatory bowel disease (IBD). Whether it correlates other markers of disease activity is unknown. The aim of this study was to correlate serum calprotectin with biochemical and histological measures of intestinal inflammation.
Materials and methods:
TNBS colitis was induced in wistar rats, and serial blood samples were collected at 0, 3, and 12 days. Animals were subsequently sacrificed for pathological evaluation at day 12. Serum calprotectin and cytokines were measured by ELISA. Pathologic changes were classified at the macroscopic and microscopic levels.
TNBS colitis induced elevated serum calprotectin, TNF and IL-6 within 24 h. Levels of serum calprotectin remained elevated in parallel to persistence of loose stool and weight loss to day 12. Serum calprotectin levels correlated with serum levels of TNF-α and IL6 (p < 0.001), but not CRP. Animals with liquid stool had significantly higher levels of serum calprotectin than control animals. There was a correlation between macroscopic colitis scores, and levels of serum calprotectin.
Serum calprotectin levels correlate with biochemical and histological markers of inflammation in TNBS colitis. This biomarker may have potential for diagnostic use in patients with IBD.
[Show abstract][Hide abstract] ABSTRACT: and Aim
. In the inflammatory bowel diseases (IBDs), many symptoms are similar to the functional disorder irritable bowel syndrome (IBS). A challenge is thus to distinguish symptoms of IBD from IBS. The aim of this study was to investigate the levels of calprotectin in IBS-positive IBD patients in remission.
. Remission was defined as a simple clinical colitis activity index (SCCAI) or simple crohn’s disease activity index (SCDAI) score of less than three and less than four, respectively. The Rome II criteria were used to identify cases, and the calprotectin ELISA test was used to quantify calprotectin in stools.
. The Rome II criteria were fulfilled in 24.6% of ulcerative colitis (UC) patients, while the comparable number for Crohn's disease (CD) was 21.4%. There was a tendency for elevated fecal calprotectin levels in IBS-positive patients, regardless of diagnosis. However, these differences were only significant in CD.
. Calprotectin levels are elevated in subgroups of IBD patients that are in remission and have coexisting IBS-like symptoms. This study underscores the clinical usefulness of a noninvasive marker to distinguish patients in need of intensified followup from those that do not need further workup.
Gastroenterology Research and Practice 02/2013; 2013(9):620707. DOI:10.1155/2013/620707 · 1.75 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Ulcerative colitis diagnosis and management represent a challenge for clinicians. The disguises of ischemia and acute infectious colitis continue to confound the diagnosis. The therapeutic options have remarkably expanded in the way of immunomodulators, biologics, or ileoanal pouch surgery, yet all carry potential considerable risks. These risks can confuse and impair patient acceptance, particularly elderly patients and men younger than 30 years. Predictors of outcome of medical and surgical therapy have improved but are far from complete. Nevertheless, therapies focused on the specific patient's condition continue to offer hope.
Mayo Clinic Proceedings 08/2013; 88(8):841-53. DOI:10.1016/j.mayocp.2013.05.001 · 6.26 Impact Factor
Ji Sung Choi, Jong Wook Bae, Sang Won Lee, Gyu Ho Choi, Jeong Eun Shin, Na-Hye Myung, Jae Seuk Park
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.